CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vivani Medical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vivani Medical Inc
1350 S. LOOP ROAD
Phone: (888) 705-7274p:888 705-7274 ALAMEDA, CA  94502  United States Ticker: VANIVANI

Business Summary
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its segments include the Biopharm Division and Neurostimulation Division. Its pipeline includes NPM-139, NPM-133, NPM-115 and OKV-119. NPM-139 is a six-month, semaglutide implant under development for the treatment of chronic weight management. NPM-115 is an exenatide-based implant candidate also under development for the treatment of chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed for once or twice-yearly administration of medication.
(Source: 6-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Gregg G.Williams 66 1/1/2021 6/1/2009
Chief Executive Officer, Director AdamMendelsohn 43 8/30/2022 8/30/2022
Chief Financial Officer AnthonyBaldor 43 6/15/2025 6/15/2025
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Nano Precision Medical, Inc. 5858 Horton St Emeryville CA United States

Business Names
Business Name
Cortigent, Inc.
EYES
Second Sight Medical Products
Second Sight Medical Products
VANI
Vivani Medical Australia Pty Ltd

General Information
Number of Employees: 42 (As of 12/31/2025)
Outstanding Shares: 90,203,356 (As of 8/13/2026)
Shareholders: 106
Stock Exchange: NASD
Federal Tax Id: 020692322
Fax Number: (888) 717-7274


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 29, 2026